Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

Table 3

Patient profiles partitioned by the cutoff value of UAGTCR before treatments.

Group	High	Low	value
	20	23
Men/women	11/9	14/9	= 0.76
Age (years)	67.0 ± 2.5	65.4 ± 2.4	= 0.66
BMI (kg/m^2)	24.1 ± 0.7	25.4 ± 0.7	= 0.19
Treatment duration of T2D (years)	6.9 ± 1.8	7.4 ± 1.6	= 0.82
Medications
ARB	12 (60.0%)	11 (47.8%)	= 0.54
-GI	4 (20.0%)	4 (17.4%)	= 1.00
TZD	1 (5.00%)	4 (17.4%)	= 0.35

ARB: angiotensin II receptor blockers, -GI: -glucosidase inhibitors, and TZD: thiazolidines.